From rs@chdr.leidenuniv.nl Thu Jul 4 06:42:02 1996
Subject: NONMEM in drug development
Dear fellow users,
I was at the International Biometric Conference (Amsterdam) today where I was challenged by a top-consultant to the pharnmaceutical industry who claimed that the use of NONMEM in drug development was vastly overrated. He was willing to accept its use in dose-adjustment post-marketing, but he challenged me to come up with the title of a publication with data that were used for drug approval where use of NONMEM had been necessary/essential. Now I know that NONMEM is used for instance in combining results from different trials, but is any of this ever published? I think a list of these publications would be very useful in convincing `my' consultant and many like him of the use of NONMEM in drug development.
Thanks in advance,
Rik Schoemaker
CHDR, Leiden, The Netherlands
(rs@chdr.leidenuniv.nl)
****
From n.holford@auckland.ac.nz Thu Jul 4 22:39:55 1996
Subject: Re: NONMEM in drug development
Rik,
I think that trying to convince the `top' consultant by attempting to prove that NONMEM was `necessary/essential' is a priori a waste of time. Suppose you were asked to prove that SAS was `necessary/essential' could you do it? I doubt it. NONMEM and SAS are tools which are used to support the approval process. Only a fool would expect approval to be conditional on the `necessity' of using a particular tool.
A series of NONMEM based analyses were used separately and as a meta-analysis to support the approval of tacrine. The advisory committee did not state officially to what extent, if any, these analyses were pivotal. The refs can be found in Holford NHG, Peace K. The effect of tacrine and lecithin in Alzheimer's disease. A population pharmacodynamic analysis of five clinical trials. Europ. J. Clin. Pharmacol. 1994; 47:17-24.
--
Nick Holford, Dept Pharmacology & Clinical Pharmacology
University of Auckland, Private Bag 92019, Auckland, New Zealand
email:n.holford@auckland.ac.nz tel:+64(9)373-7599x6730 fax:373-7556
http://www.phm.auckland.ac.nz/Staff/NHolford/nholford.html
****
From JEAN-LOUIS.STEIMER@roche.com Fri Jul 5 00:05:13 1996
Subject: Re: NONMEM in drug development
A useful (but older) reference is the Chapter ( I sell my stuff...) Steimer JL, Vozeh S, Racine-Poon A, Holford N, O=92Neill R (1994) The population approach: rationale, methods, and applications in clinical pharmacology and drug development. In: Welling PE, Balant LP (eds) Handbook of Experimental Pharmacology, Vol. 110 Pharmacokinetics of Drugs. Springer-Verlag Berlin Heidelberg
There is a table there specifically listing the applications of the population approach in drug development, which contains 13 references between 1982 and 1992, mostly associated with NONMEM analysis. Of course, it needs updating...
But the tricky statement is Rick's mail is "where use of NONMEM had been necessary/essential...". Who can judge that? How "essential" to an approval has a t-test or any piece of software ever been? I guess it's the data that matters... At best, a statistical methodology can be rated as being useful. And that's precisely what NONMEM is. Well: An input from our colleagues in regulatory bodies may be helpful...=20
I do think that there is a balance to be found between the "overrating" and the "underrating". Rather than wasting time in discussing with "top-consultants to the pharnmaceutical industry" who underrate the methodology, let's indeed, as Rik suggests, just refer them to the literature and to current practice. More and more examples are coming, as many recent international meetings show... One approach may be to go through the publications's list that the NONMEM PRoject Group is maintaining, and to tick those papers that refer to compounds in development....Is anyone volunteering for updating the list=20 started in the chapter in that way?
Jean-Louis Steimer
****
From pascal Fri Jul 5 10:36:21 1996
Subject: Re: NONMEM in drug development
I totally agree with the answer made by Nick Holford and Jean-Louis Steimer concerning the rating of a statistical methodology in drug approval.
I would like to add that, as the "top" consultant may know, not every success story from industry is published. I'm sure, that in addition of Nick and Jean-Louis's paper, there are hundreds of big and small unpublished examples, laying around in industry.
Just to take a very small example: based on preliminary knowledge, I had several times to define an experimental design for phase I PK studies, with reduced sampling times because of ethical and/or economical reason. Each time, the study results were successfully analyzed with a population model since standard methods could not be used, and lot of samples were asved. Not published!
At last ASCPT 96 in Florida, B.G. Reignier (Hoffmann La Roche, Basle CH), had a poster (which Nick and Jean-Louis may know!) entitled: "Integration of PK/PD has improved recent Roche drug development". where he presented a survey over several years and studies of the use of PK-PD, population methods, and other advanced PK techniques used at Roche. Although not entirely focused on POP method (which makes sense since it's difficult to isolate the respective influence of all these techniques), he concluded that time savings up to several months could be quantified, and that "costs of sampling and analysis were outweighted by these benefits".
My personnal feeling is that the already accumulated results are quite impressive, considering that this complex methodology has been introduced only 20 years ago, really begins to spread out 10 years ago, has been introduced in commercial competitor new softwares only 3 years ago (competition and diversity are one of the key of success!), and is still evolving.
Pascal Girard
****
From ZIADH@fs1.pa.man.ac.uk Mon Jul 8 03:23:23 1996
Subject: Re: NONMEM in drug development
I have two manuscripts that are currently in print, one in British Journal of Clinical Pharmacology and another in Clinical Pharmacology and Therapeutics, that are to be published shortly. Both manuscripts were abstracted from regulatory submissions were very little pharmacokinetics were available from formal Phase I pharmacokinetic studies and data from Phase II/III clinical trials were used for population pharmacokinetic analysis, using NONMEM, in support of the submission. If needed, I will be more than happy to provide you with copies of the manuscripts.
Best Regards,
Dr. Ziad Hussein
Centre for Applied Pharmacokinetic Research
University of Manchester
Manchester
UK
****
From rs@chdr.leidenuniv.nl Mon Jul 8 22:09:09 1996
Subject: NONMEM in drug development
Dear NONMEM users,
As you have seen, I received number of replies regarding the challenge about the usefulness of NONMEM in drug development. I passed all information on to my consultant but additionally I would like to summarise the information perhaps for future use. Although much of the work is not published because of time-pressure in the drug development process, several publications have come up:
-Holford NHG, Peace K. The effect of tacrine and lecithin in Alzheimer's disease. A population pharmacodynamic analysis of five clinical trials. Europ. J. Clin. Pharmacol. 1994;47:17-24.
-Steimer JL, Vozeh S, Racine-Poon A, Holford N, O Neill R (1994) The population approach: rationale, methods, and applications in clinical pharmacology and drug development. In: Welling PE, Balant LP (eds) Handbook of Experimental Pharmacology, Vol. 110 Pharmacokinetics of Drugs. Springer-Verlag Berlin Heidelberg (with a table of 13 references)
-Liu and Sambol, Pharmaceutical Research, Vol. 12, No. 3, 438-445, 1995.
-Ziad Hussein. two manuscripts that are currently in print, one in British Journal of Clinical Pharmacology and another in Clinical Pharmacology and Therapeutics.
To this I would like to add:
At the PAGE96 conference (population analysis group europe) Janet Wade indicated that during the 6 months that she has been working for the swedish regulatory agency, she has received 6 protocols indicating that population analysis will be performed (as part of the NDA).
some examples of the use of NONMEM in drug development are:
-analyses which allow simulations of proposed dosage regimens before the drug is marketed.
-meta-analysis.
-to allow analysis of experimental design for phase I PK studies, with reduced sampling times because of ethical and/or economical reason.
-where very little pharmacokinetics are available from formal Phase I pharmacokinetic studies and data from Phase II/III clinical trials are used for population pharmacokinetic analysis.
I may have overcharged the issue by requiring use of NONMEM to be necessary/essential but I thought it might get the ears up! What the replies boil down to is that NONMEM may or may not be essential but it is certainly considered a very useful tool; a view which I second wholeheartedly.
Thanks for all your cooperation!
Rik Schoemaker
****
From Janet.Wade@lv.mpa.400net.tip.net Tue Jul 9 01:10:16 1996
Subject: NONMEM in drug development
Hi Rik
As a regulatory person I find it quite depressing that a `top' consultant could still be posing such a silly challenge as to the usefulness of NONMEM (or any other piece of population software) in drug development. The answers given by Nick, Jean-Louis and Pascal have, I hope, given you sufficient evidence to beat your consultant around the head with.
I firmly believe that a population approach, properly applied and reported, gives those of us in the regulatory business a much better understanding of the mechanisms that govern the pharmacokinetics and pharmacodynamics of a new drug. I also believe (even more strongly if that is possible!) that it is a highly underused approach when it comes to characterising dose response relationships. I am actively encouraging companies that come to visit us here at the MPA in Sweden to consider using the approach to better characterise dose reponse relationships.
I would like to add something further to Rik's second e-mail summarising the discussion so far. With respect to my recent presentation at PAGE 96, I have not only seen protocols in which population analyses were included but there has also been a number of reports of population analyses submitted to the agency. Some of these have been crucial in characterising covariate effects (or lack of) since traditional trials were unavailable. There has also been one instance where the population analysis provided the only believable evidence for a dose reponse relationship.
Janet R. Wade
****
From HARRISONF@cder.fda.gov Tue Jul 9 07:29:46 1996
Subject: Utility of NONMEM
I don't have the references at hand, but NONMEM has also been tested in bioequivalence:
RD Heparin, analyzed and published by the sponsor's people, around 1993 Interesting conjectures, for all low-molecular weight heparins: The macro-molecule appears to continue changing its length during storage, changing its time-PD profile when used. Subtle changes in manufacturing process might change the distribution of lengths of the macro-molecules and thereby change the time-PD profiles, changing safety and efficacy. Outcome affected whether the drug product was considered to have a sufficiently stable manufacturing process for approval, and was considered for routine GMP and showing generic bioequivalence.
? I heard a bioequivalence was done by Nancy Sambol
Although FDA generally uses AUC and Cmax to evaluate bioequivalence, for some drugs, a more rigorous model-based approach may be needed to show equivalence in safety and therapeutic effect. For example, I vaguely remember DDI having a 1-1.5 hour half life with daily dosing. DDI appears to follow a typical antibiotic "paradigm", in which the goal is to get the concentration above some threshold at which it starts to kill or prevent reproduction of the parasite, keep it there for a while, and drop back so the patient won't get unacceptable side effects. I beleive flexible, model-based tools like NONMEM may be sufficiently useful in such cases to justify the additional human labor needed for analysis and to persuade the concerned parties that the analysis is valid.
In summary, I'm sure NONMEM and similar softwares have a niche in the drug development (and treatment) process. The questions I wonder about are the current and future sizes and locations of the niche.
****
From davide@ariel.ucsf.edu Tue Jul 9 08:38:11 1996
Subject: tools and science
Dear Rik,
in reference to your "summary"
"-some examples of the use of NONMEM in drug development are:
"-analyses which allow simulations of proposed dosage regimens
before the drug is marketed.
"-meta-analysis.
"-to allow analysis of experimental design for phase I PK
"studies, with reduced sampling times because of ethical and/or
"economical reason.
"-where very little pharmacokinetics are available from formal
"Phase I pharmacokinetic studies and data from Phase II/III
"clinical trials are used for population pharmacokinetic
"analysis.
I think that what might make people suspicious about the claim of "essentiality" emerges from this "summary" where many items are pooled together without really separate what is specific to nonlinear mixed effect modeling and what it is not. Going through the items:
simulations: they can be done with many software packages
meta-analysis: this is a really complicated topic which is not even well accepted outside PK/PD modeling. The reliability of meta-analysis to reach scientific conclusions has little to do with the tools used in the meta-analysis itself. The problem is related to mixing different studies (with, e.g. different quality control) not to how to analyze the mixture!
reduced sampling: I think that a discussion is needed about what one can realy achieve doing a spare sampling phase I (or II/III) study. Of course drug companies love it, but for the wrong reason: it saves their money. That is why they are all buying it! To think otherwise is really naive. Some questions here are: Can "the mechanic" of a drug (as Jane Wade put it) be determined using sparse sampling? Experience with modeling suggests that this is not in general the case. (It is easy to come up with examples, and it is strange to think that people in regulatory agencies think otherwise.) Can sparse sampling be used to obtain, necessarily approximate, rough estimates of population mean PK parameter (Volume, Clearance, ...) when some mechanic of drug is already known. Experience suggests: yes, and this might be all that is necessary to find out from a regulatory point of view.
(note that none of the items are related, per se, to nonlinear mixed effect)
overall: I agree with Holford/Steimer. NONMEM is a tool and a real good one! What is somewhat annoying is to see some people talk or use it as if it was something magic which can make by itself bad (or good) science turn into something better.
Bests, Davide
****
From ChiangS@war.wyeth.com Thu Jul 11 09:16:04 1996
Subject: NONMEM in drug development -Reply
Hi:
While I can not offer an example to meet the challenge by that "top-consultant", I have noted something might be of interest to both of you.
At the recent FDLI workshop in D.C., June 17-18, Bob Temple recommended as a pivotal study a dose-titration study in a "good population" coupled with NONMEM analysis. You might want to ask Temple if he thinks NONMEM analysis would make a difference big enough to satisfy your challenger. Temple said as far as he knows there is no such study has been submitted.
SC.
****
From n.holford@auckland.ac.nz Thu Jul 11 17:19:45 1996
Subject: Re: NONMEM in drug development -Reply
I was at this workshop too. I dont exactly recall all the weasel words ("good population", "pivotal", "dose-titration") you cite above but I know of and Bob Temple knows of (he was on the Advisory Committee) at least one drug that was approved by the FDA in which the "pivotal" trials were supported by a NONMEM analysis which explicitly defined the dose-response relationship (that had eluded traditional methods). The design of the studies had an explicit "dose-titration" phase. The drug was tacrine. I have no idea what a "good population" might be! I have previously posted to this thread a citation to the supporting NONMEM analysis.
--
Nick Holford, Dept Pharmacology & Clinical Pharmacology
University of Auckland, Private Bag 92019, Auckland, New Zealand
email:n.holford@auckland.ac.nz tel:+64(9)373-7599x6730 fax:373-7556
http://www.phm.auckland.ac.nz/Staff/NHolford/nholford.html